DDInter23 DDInter1180
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Acrivastine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Acrivastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclobenzaprine
Acrivastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brexanolone
Acrivastine {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Acrivastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine
Acrivastine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Acrivastine may lead to a major life threatening interaction when taken with Zonisamide